JAMA Network Open
EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 7, 2021
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.15985?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060721
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
What The Study Did: In this study, short-term effectiveness of the first dose of the BNT162b2 (BioNTech/Pfizer) vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting was assessed.
Authors: Gabriel Chodick, Ph.D., of the Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, in Tel Aviv, Israel, is the corresponding author.
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.